About the Editors
Professor Xin Lu studied Biochemistry at Sichuan University and then Cancer Research at Peking Union Medical School in Beijing. She was awarded an IARC WHO fellowship to come to the Imperial Cancer Research Fund in London in 1986 and studied for her PhD under Birgit Lane. In 1993 she joined the Ludwig Institute for Cancer Research (LICR), St. Mary's Branch, Imperial College as an Assistant Member and was progressively promoted to LICR Full Member and Professor at Imperial College in 2000. In 2004, she was appointed as the Director of the LICR’s UCL Branch but moved the unit to Oxford in 2007. She is an elected Member of EMBO and Fellow of the Academy of Medical Sciences.
Professor Lu's research is focused on understanding tumour suppression and to identify molecular switches that selectively kill cancer cells. Cancer is a disease where cells grow in the wrong place at the wrong time. Regenerative medicine involves growing cells to replace the ones that were lost or damaged. Therefore, understanding molecular mechanisms that control cell growth is vital, both to stop cancer cell growth and to grow normal cells to replace the damaged ones. Professor Lu's research team has been one of the major research groups in the world to study the regulation of the tumour suppressor function of the p53 protein whose function is lost in most human cancers. The majority of nuclear import pathways are mediated by importin-cargo interactions. Yet around 50% of all nuclear proteins do not use this pathway. Through a detailed understanding of the regulation of the ASPP proteins, Professor Lu's group has identified identified a code that defines RaDAR as a novel nuclear import pathway of ankyrin repeats (AR) containing proteins. AR is a structural motif found in over 250 human proteins with diverse functions. The RaDAR (RanGDP/AR) pathway is acquired by the most common familial melanoma-associated CDKN2A mutation, leading to nuclear accumulation of mutant p16ink4a. It is frequently used by AR-containing transcriptional regulators, especially those regulating NF-ĸB/p53. All these suggest the existence of an Ankyrin repeats signaling and its role in infection and cancer.
Ivano Amelio is a Senior Scientist of the Medical Research Council (MRC) Toxicology Unit at the University of Cambridge (UK). He received his PhD in Biochemistry and Molecular Biology from University of Rome Tor Vergata (Italy), investigating the contribution of microRNA-mediated mechanisms for development and homeostasis of the epidermis. Subsequently, he did his postdoc between the University of Gent (Belgium) and the MRC Toxicology Unit (UK) investigating different aspects of p53 family function in tumour development and progression. In 2016 he received his current appointment at MRC Toxicology Unit, where his research interest includes multiple aspects of the interaction of cancer cells and tumour microenvironment, especially in relation to p53 family and the hypoxia-inducible factors. Ivano is member of the advisory boards of the Institute Pasteur (Rome, Italy) and the Russian Science Foundation. He has served as member of the editorial board of Cell Death & Disease since 2017 and of Molecular and Cellular Oncology since 2014.
KEYWORDS: p53, DNA damage response, hypoxia, miR, skin biology.
The Cell Death Discovery international Editorial Board spans the breadth of the coverage of the journal – view the full Editorial Board.